Aligos Therapeutics

ALGSNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$28.600 M

$4.58 -8.77%

Close of 6 Nov 2026

As of 6 Nov 2026, Aligos Therapeutics (ALGS) has a market capitalization of $28.6M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$2.19M

#3380 by revenue

Earnings

-$24.2M

Loss-making

Shares outstanding

6,248,440

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →

#132Pelthos TherapeuticsPTHS$36.7M
#133ElutiaELUT$34.7M
#134Aligos TherapeuticsALGS$28.6M
#135Metagenomi TherapeuticsMGX$27.7M
#136Evaxion A/SEVAX$25.5M

What if Aligos Therapeutics were worth as much as…

Open the what-if tool →

Gold $28.2T

$4,521,837

Per share 987,301× higher

Bitcoin $1.53T

$244,668.73

Per share 53,421× higher

Apple $5.02T

$803,224.59

Per share 175,377× higher

Or at a round number

$50.0M $100.0M $200.0M $500.0M

Where these numbers come from

Share counts and financials for Aligos Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.